H1B Report
Side-by-side comparison

Shire Human Genetic Therapies Inc. vs WIPRO LIMITED

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Shire Human Genetic Therapies Inc.
MARank #FEIN 04-3027191
Entity B
WIPRO LIMITED
NJRank #6FEIN 98-0154401

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricShire Human Genetic Therapies Inc.WIPRO LIMITED
Total filings29272,392
Certified %81.16%91.61%
Denied %2.05%0.37%
Withdrawn %4.45%1.37%
Cert-withdrawn %12.33%6.64%
Rank#6
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateMANJ

Outcomes — Shire Human Genetic Therapies Inc.

DOL case-status mix.

Outcome breakdown: Certified 81.2%, Cert-withdrawn 12.3%, Withdrawn 4.5%, Denied 2.1%
Outcome breakdown
OutcomeShare
Certified81.2%
Cert-withdrawn12.3%
Withdrawn4.5%
Denied2.1%
Certified81.2%
Cert-withdrawn12.3%
Withdrawn4.5%
Denied2.1%

Outcomes — WIPRO LIMITED

DOL case-status mix.

Outcome breakdown: Certified 91.6%, Cert-withdrawn 6.6%, Withdrawn 1.4%, Denied 0.4%
Outcome breakdown
OutcomeShare
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Shire Human Genetic Therapies Inc.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201015
FY201115
FY201219
FY201313
FY201428
FY201512
FY201619
FY201728
FY201842
FY201931
FY202015
FY202113
FY20222
FY20235
FY202421
FY20258
FY20266
WIPRO LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20103,039
FY20113,025
FY20127,031
FY20136,574
FY20148,104
FY201511,824
FY201610,254
FY20175,012
FY20186,067
FY20194,154
FY202094
FY2021128
FY202297
FY2023554
FY20242,296
FY20252,289
FY20261,850

Top 5 occupations — Shire Human Genetic Therapies Inc.

Top 5 occupations — WIPRO LIMITED

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.